BTK and colorectal carcinoma: Notably, the kinase domain is conserved and therefore inhibited by the available BTK-targeting drugs (Ibrutinib, Spebrutinib, etc.)which we used to demonstrate that p65BTK is an actionable target in drug-resistant colorectal carcinomas.